Edition:
United Kingdom

ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

29.37USD
4:29pm GMT
Change (% chg)

$0.40 (+1.38%)
Prev Close
$28.97
Open
$29.18
Day's High
$29.39
Day's Low
$28.96
Volume
68,823
Avg. Vol
463,078
52-wk High
$41.20
52-wk Low
$24.83

Select another date:

Tue, Nov 7 2017

BRIEF-Acadia Pharmaceuticals posts Q3 loss of $0.53 per share

* Acadia Pharmaceuticals reports third quarter 2017 financial results

BRIEF-Acadia Pharmaceuticals initiates phase III study of Pimavanserin

* Acadia Pharmaceuticals initiates phase III study of Pimavanserin in dementia-related psychosis

Big-name U.S. hedge funds shed healthcare stocks during the rally in second-quarter

NEW YORK Several big-name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U.S. stock market higher, rallying amid a Republican effort to repeal and replace President Obama's signature healthcare law.

Big-name U.S. hedge funds shed healthcare stocks during the rally in second quarter

NEW YORK Several big-name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U.S. stock market higher, rallying amid a Republican effort to repeal and replace President Obama's signature healthcare law.

BRIEF-Acadia pharmaceuticals Q2 loss per share $0.55

* Acadia pharmaceuticals reports second quarter 2017 financial results

BRIEF-ACADIA Pharmaceuticals Q2 loss per share $0.55

* ACADIA Pharmaceuticals Inc - ‍expects that full-year NUPLAZID net sales for 2017 will be between $105 million and $115 million​

Select another date: